Used primarily in the management of hypertension, this compound acts as a selective imidazoline I1 receptor agonist. It works in the central nervous system to reduce sympathetic outflow, leading to decreased peripheral vascular resistance and lower blood pressure. Unlike some other antihypertensives, it has a favorable effect on metabolic parameters, making it suitable for patients with insulin resistance or metabolic syndrome. It is often considered when first-line treatments are not well tolerated, particularly due to its lower incidence of dry cough compared to ACE inhibitors. The agent is administered orally, typically once daily, offering convenience and improved adherence.